An Update on Non-alcoholic Fatty Liver Disease and Type 2 Diabetes
| | | To ensure that you never miss an issue, please whitelist us. |
|
|
| | | Dawid Hordejuk, from Brigham and Women’s Hospital in Boston, and colleagues conducted a retrospective, longitudinal, cohort study involving 414 patients with evidence of pituitary microadenomas from magnetic resonance imaging (MRI) identified from 2003 to 2021 to assess the change over time. |
|
|
A recent study examined how metformin treatment affected non-alcoholic fatty liver disease (NAFLD) severity and metabolic parameters in patients with type 2 diabetes mellitus (T2DM). The results showed that metformin significantly reduced related biomarkers in the participants with T2DM and improved their serum lipids profile without impacting glucose control. |
| | |
| |
| |
Recent Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes have been established to help control the risks associated with this chronic condition. These guidelines are focused on reducing the risk of heart attack, stroke, and other cardiovascular diseases (CVDs) through lifestyle changes and medications. |
| | |
|
|
|
